US Multiple sclerosis Market Opportunities, Business Forecast To 2029

The global us multiple sclerosis market size was valued at USD 13,957.7 million in 2022 and is expected to grow at a 6.2% CAGR during the forecast period 2023 to 2029. The primary drivers of the expansion of the US multiple sclerosis market include the increasing prevalence of multiple sclerosis among the young adults. Support of the government in the treatment of multiple sclerosis in the region. The growing focus of companies on the pipeline drugs for multiple sclerosis is also boosting the multiple sclerosis market growth in the US.

View the detailed report description here - https://precisionbusinessinsights.com/market-reports/us-multiple-sclerosis-market

Immunomodulator Segment is expected to Dominate the Multiple sclerosis Market:
Based on the Drug class, the US Multiple sclerosis market is segmented into immunomodulators, immunosuppressants, interferons, and others. The immunomodulators segment is expected to account for a larger revenue share in the US multiple sclerosis market. Increase in treatment options and new product launches for multiple sclerosis is expected to propel the growth of this segment. For instance, in January 2020, Novartis announced the approval of mayzent by European commission for the cure secondary progressive of multiple sclerosis in adults. Other segments like monoclonal antibody products and antineoplastics have become one of the most efficient treatments for reducing relapses multiple sclerosis.

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players:
The US Multiple sclerosis market further reveals that the key players are increasingly adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share and gain significant geographic presence across the region. For instance, In June 2022, Sandoz launched a generic drug named Dimethyl Fumarate Hexal, approved for relapsing-remitting multiple sclerosis treatment for adults. In March 2021, Jansenn Pharmaceuticals, announced US FDA approval for Ponvory, an oral selective sphingosine-1-phosphate receptor 1 modulator to treat relapsing multiple sclerosis in adults. In September 2021, TG therapeutics, announced the submission of Biologics license application to US FDA requesting for the approval of ublituximab.

The US Multiple sclerosis market is segmented based on the drug class, route of administration, distribution channel.

Request sample report at https://precisionbusinessinsights.com/request-sample/?product_id=411683

Based on the Drug class, the market is segmented into the following:
• Immunomodulators
• Immunosuppressants
• Interferons
• Others

Based on the Route of administration, the market is segmented into the following:
• Oral
• Intravenous
• Intramuscular
• Subcutaneous

Based on the Distribution channel, the market is segmented into the following:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Key players profiles in the multiple sclerosis market report are Biogen, Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co, Sanofi, Teva Pharmaceuticals, Jansenn Pharmaceuticals Inc., Bristol-Meyers Squibb Company

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.